We have issued an updated research report on Koninklijke Philips Electronics N.V. PHG on Dec 8, 2015. Of late, the company has been leveraging its comprehensive performance improvement and change program called Accelerate! to realize the value potential and speed up growth via augmenting both innovation and operational execution.
In recent times, Philips launched IntelliSpace Portal 8.0, the latest in its series of data sharing, analytics and visualization platforms, seeking to strengthen its position in healthcare informatics market. This apart, Philips showcased its extensive portfolio of “data-driven” healthcare solutions at the 2015 RSNA that was held in Chicago. Solutions that were exhibited on this platform included Diagnostic X-Ray Suite, IQon Spectral CT, Ultrasound Portfolio, Vereos Digital PET/CT and Image Guided Therapy.
Also, the company introduced ScanWise Implant, a Magnetic Resonance Imaging (MRI)-guided user interface and automatic scan parameter selection device, at the ongoing 100th annual meeting of the Radiological Society of North America (“RSNA”) in Chicago. The first-of-its kind device is the latest addition to the company’s diagnostic imaging solutions portfolio.
Alongside, Philips ramped up the market popularity of its Philips Norelco brand shavers with a splendid celebrity endorsement program. Apart from creating a commercial featuring a celebrity, Philips is working to ensure greater sales of its Norelco shavers through a wide network of distributional channels. The product is available in renowned online and departmental stores such as Amazon.com, Inc. AMZN, Target Corp. TGT and Wal-Mart Stores Inc. WMT.
The Accelerate! program continues to drive improvements across the organization and segments of Philips, thereby acting as a key driver of growth. It has also contributed toward developing a customer-centric approach and providing superior customer service, which has translated into cost productivity and better performance. Given the concentrated effort of the company in this domain, we expect this to continue going forward too.
Echoing similar sentiments, over the last 60 days, the Zacks Consensus Estimate for 2015 and 2016 earnings per share increased by about 4.3% and 0.5%, respectively to $1.46 and $2.05, respectively. Consequently, the company currently sports a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment